Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Institute Of Basic Medical Sciences Cams has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, so the pending work follows separate examination paths.
ARCORIA, PAUL JOSEPH is the busiest examiner, with 1 pending matter. The data does not show examiner concentration. Prosecution review should account for the distinct art unit and examiner context of each matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARCORIA, PAUL JOSEPH | 1 | 100.0% | +0.0% |
| JAVANMARD, SAHAR | 1 | 64.9% | +34.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18740951 | USE OF HEMATOPOIETIC CELL KINASE (HCK) INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS | ARCORIA, PAUL JOSEPH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18741100 | USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS | JAVANMARD, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18741100 | USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS | JAVANMARD, SAHAR | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18740951 | USE OF HEMATOPOIETIC CELL KINASE (HCK) INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS | ARCORIA, PAUL JOSEPH | 1621 | §103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18741100 | USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS | JAVANMARD, SAHAR | 1622 | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitute Of Basic Medical Sciences Cams has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Paul Joseph Arcoria has the most, with 1 of Institute Of Basic Medical Sciences Cams's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
